Co-treatment of non-steroidal anti-inflammatory drug-exacerbated respiratory disease with dupilumab and aspirin therapy after desensitization

Kathleen M Buchheit; Jonathan Hacker; Rie Maurer; Alanna McGill; Tessa Ryan; Jillian C Bensko; Tanya M Laidlaw

doi:10.1111/cea.14348

Co-treatment of non-steroidal anti-inflammatory drug-exacerbated respiratory disease with dupilumab and aspirin therapy after desensitization

Clin Exp Allergy. 2023 Sep;53(9):974-977. doi: 10.1111/cea.14348. Epub 2023 May 29.

Authors

Kathleen M Buchheit¹, Jonathan Hacker², Rie Maurer³, Alanna McGill², Tessa Ryan², Jillian C Bensko², Tanya M Laidlaw¹

Affiliations

¹ Division of Allergy and Clinical Immunology, Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA.
² Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
³ Center for Clinical Investigation, Brigham and Women's Hospital, Boston, Massachusetts, USA.

PMID: 37246613
PMCID: PMC10524624 (available on 2024-09-01)
DOI: 10.1111/cea.14348

No abstract available

Keywords: NSAID-exacerbated respiratory disease; aspirin desensitization; aspirin therapy after desensitization; aspirin-exacerbated respiratory disease; asthma; chronic rhinosinusitis; dupilumab; nasal polyps.

Publication types

Letter
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal / adverse effects
Antibodies, Monoclonal, Humanized / adverse effects
Aspirin / adverse effects
Asthma, Aspirin-Induced* / diagnosis
Asthma, Aspirin-Induced* / drug therapy
Chronic Disease
Desensitization, Immunologic
Humans
Nasal Polyps* / drug therapy
Respiratory Tract Diseases* / drug therapy
Rhinitis* / drug therapy

Substances

dupilumab
Anti-Inflammatory Agents, Non-Steroidal
Aspirin
Antibodies, Monoclonal, Humanized

Publication types

MeSH terms

Substances

Grants and funding